Aptose Announces Adjournment of its Special Meeting of Shareholders
August 15 2024 - 3:30PM
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO,
TSX: APS), a clinical-stage precision oncology company developing
highly differentiated oral targeted agents to treat hematologic
malignancies, today announced that its special meeting of
shareholders (the "Meeting") convened on August 15, 2024, at 1:00
p.m. (ET) has been adjourned to September 5, 2024 at 1 p.m. (ET),
without business being considered, due to a lack of quorum.
At the time the Meeting was adjourned, proxies
had been submitted by shareholders representing 32.76% of the
Company's common shares outstanding and entitled to vote, which did
not constitute the requisite 331/3% quorum pursuant to the
Company's by-laws. Based on the votes cast by proxy to date, all
resolutions currently have the requisite levels of support from
shareholders. The board of directors of Aptose believes that the
approval of all matters set out in the Company's proxy statement
dated July 11, 2024 (the "Proxy Statement") is in the best
interests of the Company and its shareholders.
The deadline for submission of proxies has been
extended to September 4, 2024 at 1 p.m. (ET). Proxies previously
submitted with respect to the Meeting will be voted on all
proposals at the adjourned Meeting unless properly revoked and
shareholders who have previously submitted a proxy or otherwise
voted need not take any action.
The details of the Meeting, including how to attend
the Meeting, are set out in the Proxy Statement. The record date
for the determination of shareholders entitled to vote at the
Meeting remains July 15, 2024.
To participate online, please use the following
information:Link: web.lumiagm.com/472225818 Password:
aptose2024Registered Shareholder Number: Listed on your form of
Proxy
About Aptose
Aptose Biosciences is a clinical-stage
biotechnology company committed to developing precision medicines
addressing unmet medical needs in oncology, with an initial focus
on hematology. The Company's small molecule cancer therapeutics
pipeline includes products designed to provide single agent
efficacy and to enhance the efficacy of other anti-cancer therapies
and regimens without overlapping toxicities. The Company’s lead
clinical-stage compound tuspetinib (TUS), is an oral kinase
inhibitor that has demonstrated activity as a monotherapy and in
combination therapy in patients with relapsed or refractory acute
myeloid leukemia (AML), and is being developed as a frontline
triplet therapy in newly diagnosed AML. For more information,
please visit www.aptose.com.
Forward Looking Statements
This press release may contain forward-looking
statements within the meaning of Canadian and U.S. securities laws,
including statements relating to the Company’s plans, objectives,
expectations and intentions and other statements including words
such as “continue”, “expect”, “intend”, “will”, “should”, “would”,
“may”, and other similar expressions. Such statements reflect our
current views with respect to future events and are subject to
risks and uncertainties and are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by us
are inherently subject to significant business, economic,
competitive, political and social uncertainties and contingencies.
Many factors could cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements described in this press release. Such
factors could include, among others: our ability to remain
compliant with Nasdaq listing requirements and other risks detailed
from time-to-time in our ongoing quarterly filings, annual
information forms, annual reports and annual filings with Canadian
securities regulators and the United States Securities and Exchange
Commission.
Should one or more of these risks or
uncertainties materialize, or should the assumptions set out in the
section entitled "Risk Factors" in our filings with Canadian
securities regulators and the United States Securities and Exchange
Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described
herein. These forward-looking statements are made as of the date of
this press release and we do not intend, and do not assume any
obligation, to update these forward-looking statements, except as
required by law. We cannot assure you that such statements will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements
due to the inherent uncertainty therein.
For further information, please contact:
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Nov 2023 to Nov 2024